| Autor: |
Santos JMO; Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. joana.oliveira.santos@ipoporto.min-saude.pt.; Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal. joana.oliveira.santos@ipoporto.min-saude.pt.; Research Department of the Portuguese League Against Cancer⁻Regional Nucleus of the North (Liga Portuguesa Contra o Cancro⁻Núcleo Regional do Norte), 4200-177 Porto, Portugal. joana.oliveira.santos@ipoporto.min-saude.pt., Peixoto da Silva S; Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. peixotodasilva.sara@gmail.com.; Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal. peixotodasilva.sara@gmail.com., Costa NR; Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. maria.vieira.costa@ipoporto.min-saude.pt., Gil da Costa RM; Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. rmcosta@fe.up.pt.; Center for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5001-911 Vila Real, Portugal. rmcosta@fe.up.pt., Medeiros R; Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. ruimedei@ipoporto.min-saude.pt.; Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal. ruimedei@ipoporto.min-saude.pt.; Research Department of the Portuguese League Against Cancer⁻Regional Nucleus of the North (Liga Portuguesa Contra o Cancro⁻Núcleo Regional do Norte), 4200-177 Porto, Portugal. ruimedei@ipoporto.min-saude.pt.; Virology Service, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal. ruimedei@ipoporto.min-saude.pt.; Biomedical Research Center (CEBIMED), Faculty of Health Sciences of the Fernando Pessoa University, 4249-004 Porto, Portugal. ruimedei@ipoporto.min-saude.pt. |
| Abstrakt: |
High-risk human papillomavirus (HPV)-driven cancers represent a major health concern worldwide. Despite the constant effort to develop and promote vaccination against HPVs, there is still a high percentage of non-vaccinated population. Furthermore, secondary prevention programs are not ubiquitous worldwide and not widely followed. Metastatic disease is the cause of the great majority of cancer-associated deaths, making it essential to determine its underlying mechanisms and to identify actionable anti-metastatic targets. Within certain types of cancer (e.g., head and neck), HPV-positive tumors show different dissemination patterns when compared with their HPV-negative counterparts, implicating HPV-related factors in the metastatic process. Among the many groups of biomolecules dysregulated by HPV, microRNAs have recently emerged as key regulators of carcinogenesis, able to control complex processes like cancer metastization. In this review, we present recent data on the role of microRNAs in the metastization of HPV-related cancers and on their possible clinical relevance as biomarkers of metastatic disease and/or as therapeutic targets. |
